Literature DB >> 17020431

Management of sepsis in the critically ill patient: key aspects.

Jean-Louis Vincent1.   

Abstract

Severe sepsis is a major cause of morbidity and mortality in the critically ill patient. Management involves identification and treatment of the underlying causative infection, with antimicrobial agents and surgery where necessary, haemodynamic resuscitation with fluids and vasoactive agents, steroids (for septic shock) and immunomodulation with drotrecogin-alpha (activated), where not contraindicated. Every effort must be made to identify sepsis early so as to optimise the patient's chances of a good outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020431     DOI: 10.1517/14656566.7.15.2037

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  Emerging therapeutic targets of sepsis-associated acute kidney injury.

Authors:  Sundararaman Swaminathan; Mitchell H Rosner; Mark D Okusa
Journal:  Semin Nephrol       Date:  2015-01       Impact factor: 5.299

Review 2.  MicroRNA as an Early Biomarker of Neonatal Sepsis.

Authors:  Martin Jouza; Julia Bohosova; Andrea Stanikova; Jakub Pecl; Ondrej Slaby; Petr Jabandziev
Journal:  Front Pediatr       Date:  2022-05-09       Impact factor: 3.569

Review 3.  Current trends in inflammatory and immunomodulatory mediators in sepsis.

Authors:  Monowar Aziz; Asha Jacob; Weng-Lang Yang; Akihisa Matsuda; Ping Wang
Journal:  J Leukoc Biol       Date:  2012-11-07       Impact factor: 4.962

Review 4.  Non-coding RNA: a potential biomarker and therapeutic target for sepsis.

Authors:  Tie-Ning Zhang; Da Li; Jing Xia; Qi-Jun Wu; Ri Wen; Ni Yang; Chun-Feng Liu
Journal:  Oncotarget       Date:  2017-10-10

Review 5.  Circulating MicroRNAs as Biomarkers for Sepsis.

Authors:  Fabian Benz; Sanchari Roy; Christian Trautwein; Christoph Roderburg; Tom Luedde
Journal:  Int J Mol Sci       Date:  2016-01-09       Impact factor: 5.923

6.  Clinical significance of the serum miR-455-5p expression in patients with neonatal sepsis.

Authors:  Yue-Yan Mao; Chang Su; Cheng-Chao Fang; Xiao-Ping Fan; Li-Ping Wang; Shan-Shan Zhu; Hai-Ming Yao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.